Products
Glibenfazh
Pharmacotherapeutic group
Oral hypoglycemic agent (second generation sulfonylurea derivative + biguanide)International name
Glibenclamide + MetforminDosage form
TabletsOral hypoglycemic drug combination, second generation sulfonylurea derivative.
It has both pancreatic and extra-pancreatic effects.
Glibenclamide stimulates insulin secretion through lowering the threshold concentration for glucose-induced insulin secretion at pancreatic beta-cells, improving insulin sensitivity and insulin binding to target cells, increasing insulin secretion, improving insulin-stimulated glucose uptake in muscle and liver, and inhibiting adipose tissue lipolysis. It acts in the second phase of insulin secretion.
Metformin inhibits hepatic gluconeogenesis, reduces intestinal glucose absorption, improves glucose utilisation in muscles, and reduces serum levels of triglycerides and cholesterol. It also increases insulin binding to receptors (no therapeutic effect is observed in the absence of insulin in blood). It does not produce hypoglycemia effects.